Human respiratory syncytial virus (RSV) causes severe disease in young infants. Besides young age, prematurity and congenital cardiopulmonary disease are known risk factors for severe disease. However, most children admitted to the hospital with RSV are previously healthy. To identify those at risk for severe disease, biomarkers are needed. In the RESCEU case-control study we established biomarkers predictive of, or associated with, lower respiratory tract RSV infection and disease severity. In this follow-up study the detected biomarkers will be validated.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences.
© 2023 | IMI-Promise
